Drug Profile
Piperacillin/tazobactam - Yuhan Corporation
Alternative Names: YH-1177; YH-1177DLatest Information Update: 29 Sep 2021
Price :
$50
*
At a glance
- Originator Yuhan
- Class 2 ring heterocyclic compounds; Antibacterials; Penicillins; Small molecules; Sulfones; Triazoles
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors; Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Otitis media
Most Recent Events
- 29 Sep 2021 Discontinued - Phase-I/II for Otitis media in South Korea (Otic) prior to September 2021 (Yuhan Corporation pipeline, September 2021)
- 13 Apr 2017 Yuhan Corporation terminates a phase I/II trial in Otitis media in South Korea (Otic) (NCT02817347)
- 01 Jul 2016 Yuhan Corporation plans a phase I/II trial for Otitis media in South Korea (NCT02817347)